[1] WORLD HEALTH ORGANIZATION.Global tuberculosis report 2022[EB/OL].https://www.who.int/teams/globaltuberculosis-programme/tb-reports/global-tuberculosisreport-2022. [2] VAN DEN ELSEN SHJ, AKKERMAN OW, WESSELS M, et al. Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid[J]. Eur Respir J, 2020, 56(4):2000803. [3] PRAHL JB, JOHANSEN IS, FRIMODT-M LLER N, el al. Clinical significance of 2-hour plasma concentrations of first-line tuberculosis drugs[D].lnterscience Conference on Anti-microbial Agents and Chemotherapy, Denver, CO2013. [4] SIN JH, ELSHABOURY RH, HURTADO RM, et al.Therapeutic drug monitoring of antitubercular agents for disseminated Mycobacterium tuberculosis during intermittent haemodialysis and continuous venovenous haemofiltration[J]. Clin Pharm Ther, 2018, 2(43):291-295. [5] CHAWLA PK, UDWADIA ZF, SOMAN R, et al.Importance of Therapeutic Drug Monitoring of Rifampicin[J]. J Assoc Physicians India, 2016, 8(64):68-72. [6] 赵凯, 温立鸿. 服用利福平后2h和6h血药浓度作为药峰浓度指导临床用药的可行性研究[J]. 中国合理用药探索, 2021,18(6):54-57. [7] 张相林. 治疗药物检测临床应用手册[M]. 北京:人民卫生出版社, 2020:40-50. [8] 周俊, 吕小会, 郑修齐, 等. 三种抗结核药物血药浓度调控成功率的比较分析[J]. 中国防痨杂志, 2018, 40(9):969-972. [9] MALONE RS, FISH DN, SPIEGEL DM, et al.The effect of hemodi- alysis on isoniazid, rifampin, pyrazinamide, and ethambutol[J]. Am J Respir Crit Care Med, 1999, 159(5 Pt 1):1580-1584. [10] WHO Guidelines Approved by the Guidelines Review Committee. T reatment of Tuberculosis: Guidelines. Geneva: World Health Organization[R]. World Health Organization, Copyright 2010. [11] ERWIN ER, ADDISON AP, JOHN SF, et al.Pharmacokinetics of isoniazid: The good, the bad, and the alternatives[J].Tuberculosis, 2019, (116):66-70. [12] PELOQUIN CA, JARESKO GS, YONG CL, et al.Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide[J]. Antimicrob Agents Chemother, 1997 ,41(12): 2670-2679. [13] 中华医学会结核病学分会.抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42(5):343-356. [14] ZHAO G, CHEN M, SUN L, et al.Analysis of influencing factors on the plasma concentration of first-line anti-tuberculosis drugs-a single-center retrospective cohort study[J]. Annals of translational medicine, 2022, 8(10):461-461. [15] WOO J, CHEUNG W, CHAN R, et al.In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein[J]. Clin Biochem, 1996, 29(2):175-177. [16] 张培泽, 郑俊峰, 曹炜鹏, 等. 服用利福平后两个时间段监测血药浓度的研究[J]. 中国防痨杂志, 2020, 42(5):493-497. [17] 魏香兰, 方如塘, 师延峰, 等. 抗结核药物的血药浓度监测结果分析[J]. 中国医院药学杂志,2015, 21(35):1918-1921. [18] SAKTIAWATI AMI, HARKEMA M, SETYAWAN A, et al.Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.[J].Clin Pharmacokinet,2019,11(58):1445-1454. [19] 卢春容, 谭卫国, 卓志鹏, 等. 年深圳市结核病细菌耐异烟肼、利福平流行趋势分析[J/CD]. 新发传染病电子杂志, 2017, 2(1):10-13. [20] WILKKINS JJ, SAVIC RM, KARLSSON MO, et al.Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption[J]. Antimicrob Agents Chemother, 2008, 52(6):2138-2148. [21] CURIE AHN, KOOK-HWAN OH,KIWON KIM, et al.Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin[J]. Perit Dial Int, 2003, 23(4):362-367. |